Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2014 Earnings Presentation
9 slides from Anika Therapeutics's earnings presentation, Oct 30, 2014
Slide 1: Third Quarter 2014 Investor Conference Call
Anika Therapeutics, Inc. Third Quarter 2014 Investor Conference Call October 30, 2014 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in this presentation which are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known a
Slide 3: Overview
Overview Strong third-quarter results • Total revenue up 24% to $22.1M • Orthobiologics product revenue up 47% year over year Driven by U.S. revenue of Orthovisc ® as well as product revenue associated with Monovisc® U.S. launch • Surgical and Dermal franchises also report YOY growth • Ophthalmic re
Slide 4: Income Statement Highlights
Income Statement Highlights Solid top- and bottom-line performance in Q3 2014 Dollars in millions, Q3 2013 Q3 2014 %Δ except per- share amounts Total Revenue $17.8 $22.1 24% Product Gross Margin 68% 74% Operating Expenses $10.0 $11.8 18% Operating Income $7.8 $10.3 32% Net Income $5.0 $6.2 24% Dilut
Slide 5: Balance Sheet Highlights
Balance Sheet Highlights Increased cash and strong working capital position (In millions) 12/31/13 9/30/14 $28M cash increase Cash and Investments $63.3 $91.8 • Strong cash from operations Working Capital $85.3 $122.2 • U.S. Monovisc® milestone payments earned in 1H 2014 Stockholders’ Equity $135.6
Slide 6: Orthobiologics Highlights
Orthobiologics Highlights Progress on global viscosupplementation market share strategy • Strategic goal: achieve 15% global viscosupplementation market share by the end of 2018 I. Leverage U.S. brand leadership to drive global Monovisc® and Orthovisc® growth II. Expand international distribution ne
Slide 7: Orthobiologics Highlights
Orthobiologics Highlights Progress on new product development activities Cingal® • On track to complete clinical trial data analysis and submit CE Mark application by year-end 2014 or shortly thereafter • Initiated planning activities for a safety extension study of current Cingal trial, expect to c
Slide 8: 2014 Business Outlook
2014 Business Outlook Well-positioned for continued revenue growth and profitability • U.S. viscosupplementation demand steadily improved since slow 1H ‘14 and expect FY2014 revenue to outperform market growth rate • Cingal® and HyalofastTM advancing toward commercialization • Expanded organizationa
Slide 9: Third Quarter 2014 Investor Conference Call
Anika Therapeutics, Inc. Third Quarter 2014 Investor Conference Call October 30, 2014 9